TN-401 / Tenaya Therap - LARVOL DELTA

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine (GlobeNewswire) - "Tenaya Therapeutics, Inc...today announced that the California Institute for Regenerative Medicine (CIRM), a state of California Agency that funds regenerative medicine, stem cell, and gene therapy research, has awarded Tenaya Therapeutics an $8.0 million CLIN2 grant. Proceeds from the grant will help fund clinical trial costs for Tenaya’s ongoing Phase 1b RIDGE-1 clinical trial of TN-401 gene therapy...'we look forward to sharing initial data from the low-dose cohort in the second half of this year.'"

Financing • P1 data • Cardiomyopathy • Cardiovascular

RIDGE-1: Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Tenaya Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular

RIDGE-1: Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Tenaya Therapeutics

New P1 trial • Cardiomyopathy • Cardiovascular